Ionis Pharmaceuticals (BMV:IONS *) - Aandelenkoers, Nieuws & Analyse

IONS * Overzicht aandelen

Ionis Pharmaceuticals, Inc. ontdekt en ontwikkelt therapeutica gericht op RNA in de Verenigde Staten. Meer informatie

IONS * fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 21.86% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Ionis Pharmaceuticals, Inc. Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$37.4b

Hualan Biological Engineering

SZSE:002007

CN¥30.5b

Abcam

NasdaqGS:ABCM

US$5.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ionis Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$720.55
52 Week Hoogtepunt	US$900.00
52 Week Laag	US$720.55
Bèta	0.39
11 maand verandering	-5.81%
3 maanden verandering	-19.94%
1 Jaar Verandering	n/a
33 jaar verandering	18.70%
5 jaar verandering	-32.55%
Verandering sinds IPO	-46.80%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	IONS *	MX Biotechs	MX Markt
7D	-7.9%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe IONS * presteerde ten opzichte van de MX Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe IONS * presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is IONS *'s price volatile compared to industry and market?
IONS * volatility
IONS * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: De aandelenkoers van IONS * is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van IONS * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1989	927	Brett Monia	www.ionispharma.com

Ionis Pharmaceuticals, Inc. ontdekt en ontwikkelt therapeutica gericht op RNA in de Verenigde Staten. Het bedrijf biedt SPINRAZA voor spinale musculaire atrofie (SMA) bij pediatrische en volwassen patiënten; TEGSEDI, een antisense injectie voor de behandeling van polyneuropathie veroorzaakt door erfelijke transthyretine amyloïdose bij volwassenen; en WAYLIVRA, een antisense geneesmiddel voor de behandeling van familiair chylomicronemie syndroom (FCS) en familiaire partiële lipodystrofie. Het ontwikkelt ook geneesmiddelen voor verschillende indicaties die zich in fase 3-studie bevinden, waaronder Eplontersen als maandelijkse zelfinjectie onderhuids voor de behandeling van alle vormen van ATTR; Olezarsen voor patiënten met FCS en ernstige hypertriglyceridemie (SHTG); Donidalorsen voor patiënten met erfelijk angio-oedeem; ION363 voor patiënten met amyotrofische laterale sclerose; Tofersen om de productie van superoxide dismutase 1 te remmen; Pelacarsen voor patiënten met hart- en vaatziekten en verhoogde lipoproteïne(a); en Bepirovirsen om de productie van virale eiwitten geassocieerd met het hepatitis B-virus te remmen.

Ionis Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Ionis Pharmaceuticals zich tot de beurswaarde?
IONS * fundamentele statistieken
Marktkapitalisatie	Mex$109.98b
Inkomsten(TTM)	-Mex$7.35b
Inkomsten(TTM)	Mex$16.45b

6.7x

P/S-verhouding

-15.0x

Koers/Winstverhouding

Is IONS * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IONS * resultatenrekening (TTM)
Inkomsten	US$803.07m
Kosten van inkomsten	US$917.98m
Brutowinst	-US$114.91m
Overige uitgaven	US$243.90m
Inkomsten	-US$358.81m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.27
Brutomarge	-14.31%
Nettowinstmarge	-44.68%
Schuld/Eigen Vermogen Verhouding	275.7%

Hoe presteerde IONS * op de lange termijn?

Bekijk historische prestaties en vergelijking

IONS * Overzicht aandelen

Beloningen

Risicoanalyse

Ionis Pharmaceuticals, Inc. Concurrenten

BMV:LAB B

Mex$24.9b

SEHK:6990

HK$37.4b

SZSE:002007

CN¥30.5b

NasdaqGS:ABCM

US$5.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Insufficient new directors

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Recent updates

Insufficient new directors

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Insufficient new directors

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Insufficient new directors

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)